Home › Mga Autoimmune na Sakit › Iowa
Pag-aaral pangklinika para sa Mga Autoimmune na Sakit sa Iowa
7 pag-aaral para sa Mga Autoimmune na Sakit ang naghahanap ng mga kalahok sa mga site sa Iowa.
Mga Lungsod sa Iowa
Opisyal na teksto ng pag-aaral (English)
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- The University of Iowa, Iowa City
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT06722235A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- University of Iowa, Iowa City
Nagre-recruitPhase 1
Edad 18 hanggang 74 · Lahat ng kasarian · Na-update Set 10, 2026 · NCT07085104A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- The University of Iowa, Iowa City
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06948318Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
- University of Iowa Hospitals and Clinics, Iowa City
Nagre-recruitPhase 3
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT06858319A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
- University of Iowa, Iowa City
Nagre-recruitPhase 3
Edad 12 pataas · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT06056297A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Iowa, Iowa City
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT01351545A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- University of Iowa, Iowa City
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update May 29, 2026 · NCT04422912Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.